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Background. Patients with chronic kidney disease manifest
an inflammatory state relative to healthy individuals. Inflam-
mation is regulated in part by genes of the interleukin-1 (IL-1)
gene cluster. We hypothesized that polymorphisms in this gene
cluster may be associated with risk of end-stage renal disease
(ESRD).
Methods. Polymorphisms in the IL-1 gene cluster were ex-
amined in a cohort of 239 racially diverse hemodialysis (HD)
patients and 252 controls. These individuals were genotyped
for 3 single nucleotide polymorphisms (SNPs) in the IL-1a
and b genes, and a variable-number-of-tandem-repeats poly-
morphism in the IL-1 receptor antagonist gene (IL-1RN). Poly-
morphisms were analyzed by logistic regression for their inde-
pendent associations with ESRD, and the effect of allele dose
of IL-1RN on risk for ESRD was examined. The interaction
between race and genotype was also investigated.
Results. A logistic regression model demonstrated that ho-
mozygosity for allele 2 of the IL-1RN variable-number-of-
tandem-repeats (VNTR) polymorphism was associated with
ESRD independent of race (P < 0.0005). The IL-1a-889 pro-
moter SNP was associated with ESRD independent of race and
of the IL-1RN polymorphism (P = 0.04). The IL-1b-511 pro-
moter SNP is associated with ESRD, but this is accounted for
by race (P = 0.04).
Conclusion. Two polymorphisms within the IL-1 gene cluster
are associated with ESRD independent of race. This finding is
one of the strongest associations between genotype and ESRD
reported, and suggests that polymorphisms in the IL-1 gene
cluster affect the risk of development of ESRD.
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There is substantial evidence that inflammation is as-
sociated with chronic kidney disease (CKD). Individuals
with CKD have elevated levels of inflammatory markers,
such as C-reactive protein, fibrinogen, and D-dimer [1].
While kidney disease, per se, could be responsible for the
observed associations, a study using data from the sec-
ond National Health and Nutrition Examination Survey
(NHANES II) identified elevated white blood cell count
and hypoalbuminemia as factors associated with risk of
future CKD [2], suggesting that inflammation may be es-
tablished before the onset of kidney disease, and could
be a causal factor in the development or progression of
CKD.
The interleukin (IL)-1 gene products may be particu-
larly important molecular effectors in the process of in-
flammation. The IL-1 gene cluster, a 430-kb region of
chromosome 2 (2q13-21), consists of IL-1a, IL-1b , and
IL-1 receptor antagonist, as well as several recently dis-
covered genes designated IL-1F5-F10 [3]. IL-1a and b are
proinflammatory cytokines that bind to the IL-1 receptor,
while the receptor antagonist, a competitive inhibitor at
the receptor site of both molecules, down-regulates the
immune response [4, 5]. Together, these molecules medi-
ate inflammation and, via interaction with matrix metallo-
proteinases, extracellular matrix turnover in some tissues
[6].
Many polymorphisms have been mapped in the IL-
1 gene cluster. The IL-1a −889 C→T promoter sin-
gle nucleotide polymorphism (SNP), the IL-1b +3954
C→T exon 5 SNP, the IL-1b −511 C→T promoter SNP,
and the IL-1RN variable-number-of-tandem-repeats
(VNTR) polymorphism have been associated with a vari-
ety of diseases in which inflammation has been suspected
to play a role [7–10], including systemic lupus erythe-
matosus [9] and cardiovascular disease [11]. The VNTR
polymorphism is a penta-allelic 86-bp repeat in intron 2,
in which the 5-repeat polymorphism is designated “allele
2,” and is the allele most frequently associated with dis-
eases of inflammation, including kidney disease [12]. For
example, IL-1RN allele 2 has been associated with pro-
gression to ESRD in antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis [13]. However, the exact
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relationship between IL-1RN allele 2 and more common
causes of kidney disease remains unclear. While 2 studies
have demonstrated an association of IL-1RN allele 2 with
diabetic nephropathy [14, 15], 1 has not [16].
Discordant findings could be the result of several fac-
tors. They could reflect differences in study populations
because IL-1RN allele frequencies vary widely among
different populations [9, 10]. The IL-1RN allele 2 poly-
morphism may not be the true cause of the observed
disease associations; rather, the true disease association
may be a second, disease-contributing polymorphism in
linkage disequilibrium with the IL-1RN VNTR polymor-
phism. Additionally, the issue of allelic dosing, or the
number of copies of allele 2, has not always been rig-
orously examined [14, 15], presenting the possibility that
disease associations might be driven primarily by individ-
uals who are homozygous for the non–wild-type alleles.
Finally, most reports have concentrated principally on a
putative association of the IL-1RN polymorphism with
renal disease [14, 15]. However, there is evidence that
polymorphisms within the IL-1 gene cluster may be coor-
dinately regulated [17], raising the possibility that some
combination of alleles within the cluster might have func-
tional implications. In no study has a logistic regression
analysis been undertaken to rigorously examine which
polymorphisms within the IL-1 gene cluster may be asso-
ciated with ESRD.
We designed a study to clarify associations between
polymorphisms in the IL-1 gene cluster and ESRD. A
racially diverse cohort of hemodialysis (HD) patients
was assembled, along with race-matched healthy con-
trols. Subjects were genotyped for the IL-1a −889, IL-1b
+3954, IL-1b −511, and IL-1RN VNTR polymorphisms.
The strategies employing both formal haplotyping as
well as logistic regression were evaluated for appropri-
ateness in analyzing the independent and interactive ef-
fects of multiple genetic polymorphisms within the gene
cluster. Cognizant of the unique racial diversity of our
ESRD cohort, we sought to identify which polymor-
phisms are associated with ESRD, as well as to determine
whether these polymorphisms demonstrate interactive
effects with each other or with race.
METHODS
Study subjects
Patients were enrolled from 4 dialysis units within the
San Francisco Bay Area: the San Francisco Veterans Ad-
ministration Medical Center, San Francisco General Hos-
pital, University of California San Francisco-Mount Zion
Dialysis Unit, and Satellite Dialysis Center-Greenbrae.
All ESRD patients over age 18 who had been dialyzing
for at least 3 months without evidence of active inflam-
mation were eligible to participate. The protocol was ap-
proved by the Institutional Review Boards of all study
sites; patients provided written informed consent. Con-
trol samples were purchased from Coriell Cell Reposito-
ries (Camden, NJ, USA). A total of 100 Caucasians, 100
African Americans, 30 Asians, and 10 Hispanics were ob-
tained. As the number of Hispanic samples obtainable
from Coriell was limited, we collected blood from an ad-
ditional 20 individuals of self-declared Central American
origin.
DNA isolation
For DNA isolation, blood was collected in 15 mL
EDTA tubes. Blood was centrifuged within 2 hours of
collection and frozen at −70◦C. DNA isolation was per-
formed using a commercial kit for whole blood from
Gentra-Systems (Minneapolis, MN, USA).
Genotyping of IL-1a and b SNPS
The IL-1a −889, IL-1b +3954, and IL-1b −511
SNPs were determined by 5′ nuclease activity (Taqman,
Applied Biosystems, Foster City, CA, USA). This
method utilizes the 5′ nuclease activity of the Taq
polymerase along with fluorescence quenching. Primers
and probes are as follows: IL-1a −889 forward
primer 5′ GGCCACAGGAATTATAAAAGCTGAGA,
reverse primer 5′ GGGAGAAAGGAAGGCATG-
GATTTT, FAM probe CTTCAATGGTGTTGCC, VIC
probe CTTCAATGATGTTGCC; IL-1b +3954 for-
ward primer 5′ GAGGCTCCTGCAATTGACAGA,
reverse primer 5′ AGGGTGTGGGTCTCTACCTT,
FAM probe CTGTTCTCTGCCTCGGGA, VIC probe
CTGTTCTCTGCCTCAGGA; IL-1b −511 forward
primer 5′ ACCTAAACAACATGTGCTCCACA, re-
verse primer 5′ ATCGTGCACATAAGCCTCGTTA,
FAM probe CATGTGTCAAAAGAAGA, VIC probe
CATGTGTCAAAAGGAGA. Reactions were done in
5 lL, with 0.083 lL of the 40× Taqman assay mix (Ap-
plied Biosystems), 2.5 lL of 2× Taqman Master Mix, no.
UNG (Applied Biosystems), and 10 ng of sample DNA.
The reactions were run under the following conditions:
95◦C (10 min. hold), then 92◦C (15 sec.) and 60◦C (1 min.)
for 40 cycles.
Genotyping of IL-1RN VNTR
The polymorphic region within intron 2 of the IL-1RN
gene was amplified using the polymerase chain reaction
(PCR). Genomic DNA (1 ng) served as a template in a 50
lL PCR reaction. This reaction contained the following
components: 20 pmol of each forward primer (5′-
CTCAGCAACACTCCTAT-3′) and reverse primer (5′-
TCCTGGTCTGCAGGTAA-3′); Taq gold polymerase
2.5U; 0.2 mmol/L of each of the 4 deoxynucleotide-
triphosphates; and 1.5 mmol/L of magnesium chloride.
Following the initial activation period for the Taq gold
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(10 min. at 95◦C), 35 cycles of PCR were performed.
These consisted of denaturation (95◦C × 1 min.), anneal-
ing (55◦C × 1 min.), and extension (72◦C × 1 min.). The
size of the amplified products was determined by elec-
trophoresis on a 2% agarose gel.
Statistical analysis
For Hardy-Weinberg equilibrium (HWE) calculations,
we estimated the average proportion of each allele in
the population. The fourth locus, which is penta-allelic,
was collapsed into a biallelic locus (allele 2 vs. nonallele
2). We calculated the expected frequencies of each, and a
chi-square test was used to test for departure from HWE.
We also calculated the P value using an enumeration of
the trinomial probabilities under the constraint that the
number of alleles of each type is constant.
The IL-1a −889 and b +3954 SNPs are known to be
in linkage disequilibrium (LD), but the last 3 loci appear
not to be, according to previous studies [18]. We tested
for LD, within each race separately, using a likelihood
ratio test as utilized in the haplo.score package [19]. To
test the overall LD over the whole dataset, we combined
the race-specific likelihood ratio tests into a single test by
adding the log-likelihood ratios.
The combined dataset was examined for the associ-
ation between the 4 loci (3 SNPs and 1 VNTR), race,
and outcome (ESRD status). The SNPs were treated as
an exposure with 3 categories (homozygous dominant,
heterozygous, homozygous recessive). To investigate the
issue of allelic dosing, the VNTR was examined as both
a 3-category exposure and as a 2-category exposure (ho-
mozygous recessive vs. others). For the allelic-dose cal-
culations, confidence intervals for the odds ratios were
calculated using standard large-sample approximations
appropriate for generalized linear models [20].
Since allele 2 status has been previously associated with
the presence of diabetic kidney disease [14, 15], we con-
ducted separate analyses on the diabetic and nondiabetic
ESRD cases. A Fisher exact test was used to compare
allele frequencies in the 2 subgroups.
Logistic regression analysis was then employed to
study the association between ESRD status and geno-
type. We arrived at our final model using model selection
using the Akaike Information Criterion (AIC) [21]. The
criterion counterbalances 2 components of model selec-
tion: the explanatory power of the model, as measured by
the deviance (which is an analogue for residual variance
for logistic regression models), and model complexity, as
measured by the number of parameters in the model. We
always adjusted for race because differential proportions
of cases and controls between races merely reflected our
sampling strategy.
We then used forward selection: each polymorphism
was tested individually for its association with ESRD,
Table 1. Study subject characteristics
Total N 239
Age yearsa 61.2 ± 14.2
Gender
Male N (%) 156 (65)
Dialysis duration years a 3.3 ± 4
Race/ethnicity N (%)
Caucasian (non-Hispanic) 70 (29)
African American (non-Hispanic) 81 (34)
Asian American 60 (25)
Hispanic 28 (12)
Cause of ESRD N (%)





aMean ± standard deviation.
then tested individually for independent and interactive
effects with other polymorphisms, as well as with race.
RESULTS
A total of 239 HD patients and 252 healthy controls
were studied. Characteristics of the ESRD study subjects
are shown in Table 1. The ESRD patients (cases) were a
racially diverse group, typical of the population of North-
ern California. Table 2 shows the genotype frequencies at
each locus by race. Caucasian controls were in HWE at
all 4 polymorphic sites (data not shown). Caucasian cases
were in disequilibrium at the VNTR locus, as shown in
Table 3, with a larger-than-expected frequency of allele
2 homozygotes (P < 0.0001). African American controls
were in HWE; cases were also in disequilibrium at the
VNTR (P < 0.001), although there were small numbers
of allele 2 homozygotes in the African American cases
and controls. Hispanics and Asian Americans were not
tested because the numbers were smaller than in the other
2 groups.
We examined the linkage disequilibrium (LD) between
each pair of consecutive loci. Significant LD existed only
for the first 2 polymorphisms, IL-1a −889/IL-1b +3954
(P < 0.0001) and not between the other 2 consecutive
pairs. As LD did not exist across the final 3 positions, IL-
1b +3954/IL-1b −511/IL-1RN VNTR (P = 0.22), hap-
lotypes were not constructed. Given this pattern of link-
age disequilibrium, we elected to perform polymorphic
marker-based association tests rather than constructing
haplotypes [22].
We assessed for existence of an allelic-dose effect of
the IL-1 VNTR. Subjects were analyzed by the number of
copies of allele 2 (Table 4). There were significantly more
allele 2 homozygotes in the cases than in the controls (P
< 0.01). As there was no difference between heterozy-
gotes and non-2 homozygotes (that is, between heterozy-
gotes and individuals homozygous for alleles 1, 3, 4, or 5),
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Table 2. Genotype in cases and controls at the four loci by race
Genotype frequency %
IL-1a −889 IL-1b +3954 IL-1b −511 IL-1RN VNTRa
Race (N) CC CT TT CC CT TT CC CT TT Non-(2,2) 2,2
Caucasian
Cases (60) 43 54 3 52 47 1 31 52 17 74 26
Controls (99) 62 30 8 65 33 1 46 42 12 92 7
African American
Cases (81) 32 53 15 78 21 1 23 46 31 93 7
Controls (98) 39 47 14 78 20 2 11 58 31 97 3
Hispanic
Cases (29) 69 21 10 93 7 0 24 38 38 76 24
Controls (29) 66 31 3 76 24 0 17 31 52 83 17
Asian
Cases (60) 85 13 2 90 8 2 42 40 18 95 5
Controls (30) 90 10 0 97 3 0 17 60 23 100 0
aIL-1 receptor antagonist variable-number-of-tandem-repeats.
Table 3. Hardy-Weinberg Equilibrium at IL-1 VNTR, African
Americans, and Caucasians
Race Non2, non2a Non 2,2 2,2 P value
African American
Cases 63 12 6 0.001
Controls 81 14 3 0.056
Caucasian
Cases 39 13 18 0.0001
Controls 63 29 7 0.231
anon2, alleles 1, 3, 4, or 5 of the VNTR.
Table 4. Allelic dosing of IL-1 VNTR genotype, cases versus controls
Genotype Odds ratio Confidence interval
Non2, non2a Referent –
Non2,2 0.98 0.87–1.10
2,2 1.3b 1.12–1.51
anon2: alleles 1, 3, 4, or 5 of the VNTR.
bP < 0.01.
VNTR status was considered as a “2-position” variable:
individuals were either allele 2 homozygotes (“2,2”), or
were placed into a combined group made up of all others:
allele 1, 3, 4, or 5 homozygotes and heterozygotes. No al-
lelic dose effect was noted for any of the other 3 SNPs
(data not shown).
We conducted separate analyses on the diabetic
and nondiabetic ESRD cases. Results are shown in
Table 5. Allele 2 homozygosity was strongly associated
with ESRD in both subgroups; there was no difference
in the genotype distribution between diabetic and nondi-
abetic ESRD cases (P = 0.849, Fisher exact test).
A forward logistic regression model was constructed, as
shown in Table 6. The wild-type allele is designated “C,”
with the variant labeled “T.” As there were larger num-
bers of Caucasians and African Americans than Asians
(P < 0.001), race was incorporated into all models. Each
of the 4 polymorphisms was then individually tested for
Table 5. Association of IL-1RN genotype with ESRD, diabetic
versus nondiabetic cases
Cause of ESRD Non2, non2 Non2,2 2,2
Diabetes 58 24 14
Other 108 16 19
P value by Fisher exact test (2,2 vs. others): 0.849.
Table 6. Logistic regression model for ESRD incorporating genotype
and race
Odds Confidence Overall
Variablea ratio interval P valueb
Race (Caucasian) 0.001
African American 3.43 1.37–8.58
Asian 12.72 4.22–38.40
Hispanic 3.82 0.99–14.77
IL-1 VNTR (non2, non2 + non2,2) 0.0005
2,2 2.99 1.50–5.97
IL-1a -889 (CC) 0.04
CT 1.74 0.98–2.66
TT 1.44 1.07–2.92
IL-1b -511 (CC) 0.24
CT 1.54 1.13–3.09
TT 1.96 1.66–5.26
IL-1b -511 x racec 0.04
aBase case listed in parentheses.
bOverall P value is for the term in the general model, not individual categories.
cFor the IL-1b × race interaction, CC genotype in Caucasians alone was
associated with decreased risk of ESRD; for clarity, all individual race-genotype
combinations not shown.
its association with ESRD. Based on the allelic dosing re-
sults, IL-1 RN VNTR was coded as 2,2 homozygotes ver-
sus others. For the other polymorphisms, a 3-exposure
model (homozygous dominant, heterozygous, homozy-
gous recessive) was used. IL-1RN allele 2 homozy-
gosity was associated with ESRD independent of race
(P < 0.0005), but none of the other SNPs was significantly
associated with ESRD. Race and VNTR allele 2 sta-
tus were, therefore, incorporated into a base model, and
the 3 SNPs were tested for their association with ESRD
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after adjustment for these variables. Although the IL-1a
−889 promoter SNP was not significantly associated with
ESRD prior to adjustment for IL-1 VNTR allele 2, it was
independently associated with ESRD (P = 0.04) after
adjustment. IL-1a −889 genotype was then incorporated
into the model, and the 2 remaining SNPs tested for as-
sociations with ESRD after adjustment for race, VNTR
allele 2, and IL-1a −889. No significant associations were
found between the 2 remaining SNPs and ESRD.
Each polymorphism was then tested for its interaction
with race (i.e., the chance that an individual polymor-
phism has a differential association with ESRD among
races). The IL-1b −511 SNP alone interacted with race
(P = 0.04). Specifically, the homozygous wild-type pat-
tern in Caucasians was associated with a decreased risk
of ESRD compared to the other 2 genotypes. Finally, to
determine whether the association between IL-1a −889
and ESRD differed depending on IL-1 RN VNTR geno-
type, an interaction term was tested in the model. Be-
cause no interaction between IL-1a −889 and VNTR was
noted, this term was not added to the final model. The fi-
nal model therefore included terms for race, IL-1 VNTR
genotype, IL-1a −889 genotype, IL-1b −511 genotype,
and IL-1b −511 x race interaction.
DISCUSSION
In this study, 4 polymorphisms spanning the IL-1 gene
cluster were investigated for their association with ESRD.
Here we report that 2 of these polymorphisms, the IL-
1RN VNTR and the IL-1a −889 SNP, are independently
associated with ESRD in a racially heterogeneous dialysis
population.
Initially, the 4 polymorphisms were analyzed for the
presence of linkage disequilibrium to determine the suit-
ability for a strategy of haplotype analysis. We found that
while the IL-1a −889 and IL-1b +3954 SNPs were in
LD, there was only weak LD between the last 3 polymor-
phisms (IL-1b +3954, IL-1b −511, and IL-1RN VNTR).
Our results are in concert with those of Bensen et al, who
cataloged 95 polymorphisms in the IL gene cluster in a
mixed Caucasian and African American population [18].
They found an LD “trough” between IL-1b and IL-1RN,
indicating that the receptor antagonist gene was not seg-
regating in concert with genes known to be “upstream”
(IL-1a and b).
IL-1RN allele 2 has been associated with diabetic
nephropathy [15]. These findings raise the possibility
genotype-disease status (in particular, IL-1RN genotype
and ESRD) may be confounded by intermediate pheno-
types or predisposing diseases such as diabetes. Accord-
ingly, we examined whether the diabetic subgroup within
our ESRD cohort was enriched in allele 2 homozygotes;
this appears not to be the case, with no significant differ-
ences in the genotype distributions.
IL-1RN allele 2 homozygosity was associated with
ESRD independent of race in our study. That allele 2 fre-
quencies were not in HWE in our Caucasian cases (i.e.,
that these alleles were in higher-than-expected frequen-
cies in patients who have advanced to ESRD) implicates
this locus in pathogenesis of ESRD. The relationship of
the IL-1RN VNTR polymorphism and renal disease has
been examined in several previous studies. One study re-
ported an association between IL-1RN allele 2 carriage
and ESRD, with both diabetic and nondiabetic ESRD
patients having significantly higher allele carriage rate
of IL-1RN allele 2 [14], in concordance with our re-
sults. Whether homozygosity for allele 2 was a stronger
predictor of outcome than merely carriage of the al-
lele was not addressed. The reported association of al-
lele 2 by Blakemore et al added to the body of evidence
suggesting that allele 2 has an association with kidney
disease [15]. Again, association with allele 2 homozy-
gosity appears not to have been specifically examined.
Diabetic nephropathy, rather than ESRD, was also the
outcome in an analysis by Loughrey et al, in which no
association was found between IL-1RN allele 2 and case
status [16].
There are 2 possible explanations for the discordance
of findings in the literature. First, disease classification
might impact the nature and strength of association be-
tween IL-1RN allele 2 and the outcome examined. The
true allele 2 association may not be with renal disease, per
se, but with inflammation, scarring, and progression to
ESRD. If this is the case, studies examining an “interme-
diate” or “incomplete” phenotype may result in weaker
or more variable associations, as observed in the liter-
ature. Diabetics with proteinuria, such as those in the
Blakemore and Loughrey studies [15, 16] are in a “mod-
erate” stage of disease, and only a minority will progress
to ESRD. Our patients, by virtue of having ESRD, are fur-
ther advanced in the inflammatory progression of renal
disease than other study populations. In this context, IL-
1RN allele 2 may provide the true link between IL-1RN–
mediated inflammation and ESRD, and as such may be a
marker of renal disease progression [23].
Second, the true association of disease may be with
homozygosity for allele 2. We observed a clear gene-dose
effect of allele 2, in which the homozygous state was more
strongly associated with disease status than the heterozy-
gous or wild-type homozygous states. In the 2 studies
that report an association between allele 2 and outcome,
neither specifically examined the issue of allelic dosing,
although Blakemore et al reported that allele 2 was as-
sociated with diabetic nephropathy when analyzed for
allele carriage rate and allele frequency [15].
There is at least one other report of a similar allelic
dose effect of IL-1RN allele 2 on a disease condition: in a
study of IL-1 polymorphisms in coronary artery disease,
Frances et al implicate allele 2 homozygosity as a marker
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for vascular disease [11]. In one subgroup, the OR for
disease status was substantially increased in allele 2 ho-
mozygotes, a finding not noted in heterozygotes.
The observed allelic dosing in the IL-1RN VNTR could
be a functional consequence of genotype variation, such
as altered production of the gene product [24]. The dose
effect of allele 2 on receptor antagonist production has
been examined in human cultured endothelial cells [25].
Cells homozygous for the RN allele 2 produced less than
half the amount of IL-1 receptor antagonist than wild-
type homozygotes (P < 0.05), and tended to produce
less than the heterozygous cells. This same group also
demonstrated a lower level of endothelial cell popula-
tion doublings and increased cellular senescence in allele
2 homozygotes as compared to wild-type cells [24]. These
authors hypothesized that capacity for endothelial cell re-
generation is a determinant of progression of atheroscle-
rosis and vascular disease. Thus, individuals with a lower
endothelial replicative phenotype could be at increased
risk for vascular disease and, conceivably, progression to
ESRD.
IL-1a −889 allele status was also associated with ESRD
in our study. Only one other report, to our knowledge,
has investigated the IL-1a −889 SNP and its association
with renal disease. Loughrey et al found no association of
this SNP with diabetic nephropathy [16]. In our analysis,
the association of the IL-1a −889 SNP with ESRD be-
came evident only after adjustment for the effect of the
VNTR. This, together with the larger P value (P = 0.04
vs. P = 0.0005 for the VNTR) implies that the association
of this SNP with ESRD is much weaker than that of the
VNTR. There was no interaction between the polymor-
phisms uncovered in our analysis, demonstrating that one
polymorphism does not have a differential association
with ESRD dependent on the presence of another. Thus,
both polymorphisms may be implicated in true, indepen-
dent associations with ESRD, underscoring the possible
importance of the IL-1 gene cluster as a mediator of in-
flammation in the progression of chronic kidney disease
to ESRD.
At the IL-1b −511 position, there was an association
with ESRD that was accounted for by race (P = 0.04); that
is, the association of this SNP with ESRD is likely to be
the result of a differential effect among races. Specifically,
this result was driven by the lack of association of the CC
genotype with ESRD in Caucasians. No such association
was found in the other races. As this was not a generalized
finding, and as the association was marginal, this should
be considered a hypothesis-generating finding.
As typical of the dialysis population of Northern Cal-
ifornia and, increasingly, the dialysis population of the
United States, we assembled a cohort with considerable
racial diversity. This proved to be both strength and a
limitation of our study. Although our overall sample size
provided adequate power to assess associations between
genotype and ESRD, power was limited to perform race-
stratified analyses. Therefore, our control group was as-
sembled to closely match the racial distribution, and our
forward logistic regression model was constructed to ex-
amine the effects in the different groups in a single anal-
ysis, minimizing any loss of power. The racially diverse
nature of our cohort was an advantage because it is rep-
resentative of the United States dialysis population and,
thus, increases the generalizability of our results.
CONCLUSION
Specific polymorphisms in the interleukin-1 gene clus-
ter are associated with ESRD in a cohort of dialysis
patients. Both the IL-1a −889 and the IL-1RN VNTR
polymorphisms predict ESRD status independent of
race. For the VNTR polymorphisms, dose of the “delete-
rious” allele 2 provides a strong association with ESRD.
The polymorphisms do not appear to be in linkage dis-
equilibrium, implying that each is independent of each
other. For this reason, we posit that logistic regression,
rather than haplotype analysis, is the appropriate strat-
egy for detecting polymorphism-disease associations.
Logistic regression, applied for the first time to our knowl-
edge in the study of IL-1 genes in ESRD, demonstrates
the importance of multiple polymorphisms in the IL-
1 gene cluster as determinants of ESRD. Additionally,
our approach may clarify inconsistent findings in the lit-
erature because examination of independent contribu-
tions of several polymorphisms may both increase power
and detect true polymorphism-disease associations that
are inconsistent or obscured when examined individually.
Because our cohort has substantial racial diversity, the re-
sults may be more broadly applicable than those of previ-
ous findings. Our results implicate the IL-1 gene cluster as
an important target of investigation in the development
of strategies to slow progression to ESRD, and could con-
ceivably provide the basis for defined anti-inflammatory
strategies to limit renal disease progression.
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